The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. [electronic resource]
Producer: 20081204Description: 1731-40 p. digitalISSN:- 0012-186X
- Angiotensin II Type 1 Receptor Blockers -- therapeutic use
- Animals
- Apolipoproteins E -- deficiency
- Benzimidazoles -- therapeutic use
- Biphenyl Compounds
- Blood Vessels -- drug effects
- Diabetes Mellitus -- drug therapy
- Disease Models, Animal
- Fluorobenzenes -- therapeutic use
- Glycation End Products, Advanced -- metabolism
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- therapeutic use
- Inflammation -- prevention & control
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Oxidative Stress -- drug effects
- Pyrimidines -- therapeutic use
- Rosuvastatin Calcium
- Sulfonamides -- therapeutic use
- Tetrazoles -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.